Thursday, November 23, 2017
Home Academia High-dose radiation therapy as effective as surgery for aggressive prostate cancer

High-dose radiation therapy as effective as surgery for aggressive prostate cancer

brain proteins, menopause, leukemia, Sarcoma, neurodegenerative disorders, menopause, autism, Brain-gut-microbiota, Intestinal Inflammation, Parkinson’s disease, Gonorrhea, sclerosis, mammalian, bowel syndrome, pregnancy, cancer, zika virus, HIV, immunotherapy, glioblastoma, stem cells, Metabolic proteins, HIV, protein, prostate cancer, autism, heart failure, DNA, autism disorders

A study by researchers at the UCLA Jonsson Comprehensive Cancer Center provides convincing evidence that radiation-based treatments and surgery are equally effective treatments for aggressive prostate cancer. It also suggests that a particular form of radiation therapy, consisting of external radiation followed by brachytherapy (a type of radiation treatment in which a radioactive source is placed into the tumor directly) provides the best chance of preventing metastatic disease.

This study was the first of its kind to directly compare outcomes between radiation-based treatments and surgery for patients with cancers that are Gleason score nine or 10 (the highest score possible, which represents the most aggressive form of cancer).

BACKGROUND

Prostate cancer is the most common form of cancer among men in the United States, with nearly 180,000 new cases expected to be diagnosed in 2016 alone. Therefore, identifying the optimal treatment strategies for this malignancy is particularly important.

In the past oncologists suggested that surgery and radiation-based treatments offer equivalent outcomes. However, optimal treatment for prostate cancer patients remains controversial, in part because technologies and treatment strategies are continually improving. Both surgery and radiation-based treatments have vocal supporters and detractors within the medical community.

The relative efficacy of these treatments is particularly relevant for the most aggressive forms of prostate cancer, which will most likely lead to metastatic disease and eventually death. The aggressiveness of prostate cancer is dependent on many factors, one of which is the Gleason score — a grading system of how aggressive the disease appears under the microscope.

METHOD

Researchers analyzed 487 prostate cancer patients treated for Gleason scores of 9 or 10 prostate cancer between 2000 and 2013 at UCLA, the California Endocurie Therapy Center and Fox Chase Cancer Center. Institutional databases were used to identify patients, and clinical follow up was obtained.

The findings only included advanced prostate cancer patients who were treated since 2000, because the standard of care for these patients has significantly changed over time, particularly for radiation-based treatments.

IMPACT

“Our study focuses on a particularly aggressive form of prostate cancer, and provides the largest series of outcomes for patients with this diagnosis who were treated in the modern era,” said Dr. Amar Kishan, a chief resident in the department of radiation oncology at UCLA. “Our conclusions are relevant to both physicians advising patients about the effectiveness of different treatment options, and patients who would like to learn more about these options on their own.”

The treatments received by patients included in the study are much more likely to be similar to treatments being offered to patients at various medical institutions across the world today.

AUTHORS

Additional authors include Dr. Christopher King, who is the study’s senior author, Dr. Robert Reiter, Dr. Jonathan Said, Dr. Nicholas Nickols, Dr. William Aronson, Dr. Mitchell Kamrava, Dr. David Jeffrey Demanes, Dr. Michael Steinberg and Dr. Patrick Kupelian. All are members of the UCLA Jonsson Comprehensive Cancer Center.

JOURNAL

The research was published online in the journal of European Urology.

FUNDING

The research was supported by the UCLA Jonsson Comprehensive Cancer Center, California Endocurie Therapy Center and Fox Chase Cancer Center.